Facebook
Twitter
LinkedIn
Forward2024 Summit on Hematological Cancers
This CME-accredited activity, the 2024 Annual Summit on Hematologic Cancers, is a national meeting featuring leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, multiple myeloma, and lymphoma. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances along with case-based discussion in the field of hematologic malignancies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.
Target Audience
- Cancer care professionals
- Practicing medical oncologists/hematologists
- Radiation oncologists
- Pathologists
- Medical oncology and hematology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
- Pharmacists
SUPPORTERS
This meeting is supported by our Gold Sponsor Genentech.
ORGANIZING COMMITTEE
Course Director:
Binay Shah, MD, MHA - Binaytara Foundation
Co-Chairs:
Nitin Jain, MD - MD Anderson Cancer Center
Navneet Majhail, MD, MS - Sarah Cannon
Sonali Smith, MD - University of Chicago
Shaji Kumar, MD - Mayo Clinic
Abstract Committee Chairs:
Alexey Danilov, MD, PhD - City of Hope
Hetty Carraway, MD - Cleveland Clinic
Abstract Committee:
Nitin Jain, MD - MD Anderson Cancer Center
Jack Khouri, MD, FACP - Cleveland Clinic
Jayastu Senapati, MD - MD Anderson Cancer Center
Abhay Singh, MD, MPH - Cleveland Clinic
Media & Publications Committee:
Nihar Desai, MD - Princess Margaret Cancer Center
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
- Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
- Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors
- Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies
HOTEL INFORMATION
A limited number of guestrooms are reserved at the for the participants of this meeting at a discounted rate of $299 per night. The room rate doesn't include the additional charge of $20 per person per night for third and fourth person per guest room or any applicable taxes.
CUTOFF - Friday September 13, 2024
Please use the link below to reserve your room for the discounted rate. The rate is good through riday September 13, 2024.
Parking
The hotel offers short term self-parking (2-8 hours) for $24 and overnight parking (8-24 hours) for $50.
GLOBAL ONCOLOGY PROJECT
Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/
DAY 1 – Friday, October 11, 2024
All times are listed in Central Daylight Time (CDT)
12:00 PM – 01:15 PM Registration & Exhibits
01:15 PM – 01:30 PM Opening Remarks
01:30 PM – 03:00 PM Session 1 - ALL
Session Chairs: Veronika Bachanova, MD, PhD & Nitin Jain, MD
01:30 PM – 01:45 PM What have we learned from pediatric regimens in ALL? - Haydar Frangoul, MD, MS
01:45 PM – 02:00 PM CAR-T vs. Bispecifics Vs. Monoclonals in B-ALL - Marlise Luskin, MD, MSCE
02:00 PM – 02:15 PM Treatment of Ph+/Ph-like ALL - Veronika Bachanova, MD, PhD
02:15 PM – 03:00 PM Q & A and Case-Based Panel Discussion
03:00 PM – 03:30 PM Break & Exhibits
03:30 PM – 05:00 PM Session 2 - Aggressive Lymphomas
Session Chairs: Sairah Ahmed, MD & Nirav Shah, MD, MSHP
03:30 PM – 03:45 PM Updates in CAR-T therapy for aggressive lymphomas - Bhagirathbhai Dholaria, MD, MBBS
03:45 PM – 04:00 PM Focus on elderly patients with aggressive B-cell lymphomas - Sairah Ahmed, MD
04:00 PM – 04:15 PM Outpatient management of CAR-T therapy recipients - Jeremy Pantin, MD, FACP
04:15 PM – 05:00 PM Q & A and Case-Based Discussion
05:00 PM – 06:30 PM Poster Abstract Session / Reception
6:15 PM - 7:00 PM Product Theater Sponsored by Taiho Oncology in McGavock Breakout Room
Speaker: Leland Metheny, MD
*This is a Non-CME activity*
DAY 2 – Saturday, October 12, 2024
07:00 AM – 08:00 AM Registration, Exhibits & Breakfast
08:00 AM – 09:30 AM Session 3 - Multiple Myeloma - Newly Dx
Session Chairs: Nisha Joseph, MD & Muhamed Baljevic, MD, FACP
08:00 AM – 08:15 AM Triplets or quadruplets – what is the right approach for newly diagnosed MM? - Nisha Joseph, MD
08:15 AM – 08:30 AM Transplant for MM – does it still have a role? - Natalie Callander, MD
08:30 AM – 08:45 AM Maintenance approaches for MM – one, two, or more drugs? - Prashant Kapoor, MD
08:45 AM – 09:30 AM Q & A and Case-Based Discussion - Jesus Berdeja, MD
09:30 AM – 10:15 AM Break & Exhibits
Product Theater Sponsored by Servier Pharmaceuticals in McGavock Breakout Room.
Topic: IDHentifying Appropriate Patients With MDS or AML
Speaker: Harry P. Erba, MD, PhD
*This is a Non-CME activity*
10:15 AM – 10:45 AM Addressing Global Cancer Health Disparities - Building a 200-Bed Cancer Hospital In Nepal - Binay Shah, MD, MHA
10:45 AM – 12:15 PM Session 4 - AML/MDS
Session Chairs: Stephen Strickland, MD, MSCI & Alexander E. Perl, MD, MS
10:45 AM – 11:00 AM Frontline Therapy of AML in 2024 - Gautam Borthakur, MD
11:00 AM – 11:15 AM Treatment options for relapsed/refractory AML Triplets in AML. Where are we and what’s next? - Somedeb Ball, MD, MBBS
11:15 AM – 11:30 AM Venetoclax in AML/ALL. Which subsets and why? - Marina Konopleva, MD, PhD
11:30 AM – 11:45 AM Management of MDS after HMAs - Hetty Carraway, MD
11:45 AM – 12:15 PM Q & A and Case-Based Discussion - Sumeet Bhatia, MD, MBBS; Sanam Loghavi, MD
12:15 PM – 01:15 PM Lunch, Exhibits
Product Theater Sponsored by Johnson & Johnson in McGavock Breakout Room.
Topic: What's Next for Patients with 2L+ Relapsed or Refractory Multiple Myeloma
Speaker: Melhem Solh, MD
*This is a Non-CME activity*
01:15 PM – 01:45 PM Keynote: Making progress in myeloma – the need for a risk adapted management - Sagar Lonial, MD, FACP
01:45 PM – 03:15 PM Session 5 - CLL
Session Chairs: Nitin Jain, MD & Danielle Brander, MD
01:45 PM – 02:00 PM BTK or BCL2i or Both for Frontline CLL - Danielle Brander, MD
02:00 PM – 02:15 PM Pirtobrutinib, CAR T, and others. How to incorporate it in practice? - Alexey Danilov, MD, PhD
02:15 PM – 02:30 PM Richter transformation. What’s new? - Sameer Parikh, MD
02:30 PM – 03:15 PM Q & A and Case-Based Discussion
03:15 PM – 03:45 PM Break & Exhibits
03:45 PM – 05:15 PM Session 6 - Low-Grade Lymphomas
Session Chair: Sonali Smith, MD
03:45 PM – 04:00 PM Are bi-specifics really going to have a role in indolent lymphomas? - Vivek Patel, MD
04:00 PM – 04:15 PM Sequencing of treatments in 2L+ setting for follicular lymphoma - Michael Byrne, DO
04:15 PM – 04:30 PM Updates in treatment of mantle cell lymphoma - Krish Patel, MD
04:30 PM – 05:15 PM Q & A and Case-Based Discussion
05:15 PM – 06:15 PM Raise a Toast for Women in Hematology
**This is a non-CME activity**
Sponsored by Jazz Pharmaceuticals
DAY 3 – Sunday, October 13, 2024
07:00 AM – 08:00 AM Registration, Exhibits, & Breakfast
07:30 AM – 08:15 AM Oral Abstract Session *This is a non-CME Activity*
Abstract Committee Chairs:
Alexey Danilov, MD, PhD; Hetty Carraway, MD
Abstract Committee:
Nitin Jain, MD; Jack Khouri, MD, FACP; Jayastu Senapati, MD; Abhay Singh, MD, MPH
08:15 AM – 08:45 AM Keynote: Donor for all: Breaking down HLA barriers to allogeneic transplantation - Heather Stefanski, MD, PhD
08:45 AM – 10:15 AM Session 7 - CML/MPN
Session Chairs: Naveen Pemmaraju, MD & Olatoyosi Odenike, MD
08:45 AM – 09:00 AM Incorporating novel JAKi and other therapies in MF management - Naveen Pemmaraju, MD
09:00 AM – 09:15 AM Unanswered questions in CML in 2024 - Fadi Haddad, MD
09:15 AM – 09:30 AM Advanced MPN: Unanswered questions - Anand Patel, MD
09:30 AM – 10:15 AM Q & A and Case-Based Discussion - Ashwin Kishtagari, MD; Sanam Loghavi, MD
10:15 AM – 11:00 AM Break & Exhibits
Product Theater Sponsored by Johnson & Johnson in McGavock Breakout Room.
*This is a Non-CME activity*
11:00 AM – 01:00 PM Session 8 - Multiple Myeloma - R/R
Session Chairs: Melissa Alsina, MD & Shaji Kumar, MD
11:00 AM – 11:15 AM Management of early relapses in myeloma-choosing the right combination - Melissa Alsina, MD
11:15 AM – 12:00 PM Integrating immunotherapies into the treatment of relapsed MM – CART, ADC, and bispecifics - Krina Patel, MD, MSc
12:00 PM – 12:15 PM Non-immune approaches for advanced myeloma - Gurbakhash Kaur, MD
12:15 PM – 01:00 PM Q & A and Case-Based Discussion - Minoo Battiwalla, MD, MS
01:00 PM Adjourn
HOTEL INFORMATION
A limited number of guestrooms are reserved at the for the participants of this meeting at a discounted rate of $299 per night. The room rate doesn't include the additional charge of $20 per person per night for third and fourth person per guest room or any applicable taxes.
CUTOFF - Friday September 13, 2024
Please use the link below to reserve your room for the discounted rate. The rate is good through riday September 13, 2024.
Parking
The hotel offers short term self-parking (2-8 hours) for $24 and overnight parking (8-24 hours) for $50.
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Nitin Jain, MD
Shaji Kumar, MD
Navneet Majhail, MD, MS, FASTCT
Sonali Smith, MD FASCO
Sairah Ahmed, MD
Melissa Alsina
Veronika Bachanova, MD, PhD
Muhamed Baljevic, MD, FACP
Danielle Brander, MD
Nitin Jain, MD
Nisha Joseph, Associate Professor, MD
Shaji Kumar, MD
Olatoyosi Odenike
Naveen Pemmaraju
Alexander Perl, MD
Nirav Shah, MD
Sonali Smith, MD FASCO
Stephen Strickland, MD, MSCI
Sairah Ahmed, MD
Melissa Alsina
Veronika Bachanova, MD, PhD
Gautam Borthakur
Danielle Brander, MD
Michael Byrne, DO
Natalie Callander
Hetty Carraway, MD, MBA
Alexey Danilov, MD, PhD
Bhagirathbhai Dholaria, MD
Haydar Frangoul
Fadi Haddad
Nisha Joseph, Associate Professor, MD
Prashant Kapoor, MD, FACP
Gurbakhash Kaur, MD
Marina Konopleva, MD, PhD
Sagar Lonial, MD
Marlise Luskin, MD MSCE
Jeremy Pantin, MBBS, FACP
Sameer Parikh
Anand Patel, Assistant Professor of Medicine; Medical Director, Inpatient Leukemia Service
Krina Patel, MD
Krish Patel, MD
Vivek Patel
Heather Stefanski, MD PhD
Somedeb Ball, Assistant Professor of Medicine, Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN
MINOCHER BATTIWALLA, MD
Jesus Berdeja
Sumeet Bhatia
Shuang Fu, MD, PhD
Ashwin Kishtagari
Sanam Loghavi, Associate Professor
Naveen Pemmaraju
Nihar Desai, Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto
Jack Khouri, MD
Abhay Singh, MD MPH
Jayastu Senapati, MBBS, MD, DM
Acknowledgement of Commercial Support
This activity is supported with an Independent Medical Education Grant from:
- Novartis
Available Credit
- 13.50 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 13.50 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 13.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 13.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 13.50 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 13.50 Contact Hours.
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:
Link to register as an additional rep of a sponsoring company: https://education.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.